Cervical cancer is the fourth most common malignancy diagnosed in women worldwide.
Nearly all cases of cervical cancer result from infection with the human papillomavirus, and the …

Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …

Patients with high-grade serous ovarian cancer (HGSC) have experienced little
improvement in overall survival, and standard treatment has not advanced beyond platinum-based …

… Linda R. Mileshkin, MBBS 4 … de Boer SM, Powell ME, Mileshkin L, et al: Adjuvant
chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer …

PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with
previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/…

Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …

Background Although women with endometrial cancer generally have a favourable prognosis,
those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 …

Background Cancer of unknown primary ranks in the top ten cancer presentations and has
an extremely poor prognosis. Identification of the primary tumour and development of a …

This study aimed to investigate whether molecular analysis can be used to refine risk
assessment, direct adjuvant therapy, and identify actionable alterations in high-risk endometrial …

Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy
and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial …